Cargando…

Antagonistic Functions of Androgen Receptor and NF-κB in Prostate Cancer—Experimental and Computational Analyses

SIMPLE SUMMARY: The standard treatment of metastasizing prostate cancer by androgen receptor blockers fails to provide a curative therapy, with most of the patients dying from tumor relapse. We show by experimental and computational methods that androgen receptor blockade upregulates inflammatory pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Basílio, José, Hochreiter, Bernhard, Hoesel, Bastian, Sheshori, Emira, Mussbacher, Marion, Hanel, Rudolf, Schmid, Johannes A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776608/
https://www.ncbi.nlm.nih.gov/pubmed/36551650
http://dx.doi.org/10.3390/cancers14246164
Descripción
Sumario:SIMPLE SUMMARY: The standard treatment of metastasizing prostate cancer by androgen receptor blockers fails to provide a curative therapy, with most of the patients dying from tumor relapse. We show by experimental and computational methods that androgen receptor blockade upregulates inflammatory pathways, which may finally trigger survival mechanisms of cancer cells. Therefore, we hypothesize that a combined anti-inflammatory/antiandrogen treatment might be beneficial and should be tested in preclinical models as well as clinical studies of prostate cancer. ABSTRACT: Prostate cancer is very frequent and is, in many countries, the third-leading cause of cancer related death in men. While early diagnosis and treatment by surgical removal is often curative, metastasizing prostate cancer has a very bad prognosis. Based on the androgen-dependence of prostate epithelial cells, the standard treatment is blockade of the androgen receptor (AR). However, nearly all patients suffer from a tumor relapse as the metastasizing cells become AR-independent. In our study we show a counter-regulatory link between AR and NF-κB both in human cells and in mouse models of prostate cancer, implying that inhibition of AR signaling results in induction of NF-κB-dependent inflammatory pathways, which may even foster the survival of metastasizing cells. This could be shown by reporter gene assays, DNA-binding measurements, and immune-fluorescence microscopy, and furthermore by a whole set of computational methods using a variety of datasets. Interestingly, loss of PTEN, a frequent genetic alteration in prostate cancer, also causes an upregulation of NF-κB and inflammatory activity. Finally, we present a mathematical model of a dynamic network between AR, NF-κB/IκB, PI3K/PTEN, and the oncogene c-Myc, which indicates that AR blockade may upregulate c-Myc together with NF-κB, and that combined anti-AR/anti-NF-κB and anti-PI3K treatment might be beneficial.